The past 10 years have been an exciting ride for Chronic Lymphocytic Leukemia (CLL) aficionados. An overview of changes in management paradigms in CLL, ranging from insights into biology, via chemotherapy and chemoimmunotherapy to maintenance and novel drugs will be presented.
Keywords: Chemoimmunotherapy; Chronic Lymphocytic Leukemia; Ibrutinib; Idelalisib; Minimal Residual Disease; Venetoclax.